: Quantitative pupillometry has utility in research settings for measuring optic nerve and autonomic function. We configured a portable device to perform quantitative pupillometry with application to detecting unilateral optic neuropathies in the clinical setting.: Light stimuli were delivered, and pupil diameter responses recorded using customized software implemented on a commercial portable electroretinography device. Increasing pupillary constriction occurred with increasing duration and intensity of full field blue light (470 nm) stimuli in healthy subjects. Flashes of 1 s dim (50 cd/m) and bright (316 cd/m) blue light were administered to both eyes of subjects with unilateral optic neuropathies (n = 10) and controls (n = 5). Maximum pupillary constriction (C) for each stimulus was compared between control eyes and optic neuropathy eyes. C for the inter-eye difference curve (C) was compared between control and optic neuropathy subjects.: The pupil protocol lasted 15 minutes and was well tolerated by subjects. C for bright and dim stimuli was reduced in eyes with optic neuropathy compared to fellow and control eyes ( < .0005 for all). Inter-eye C was larger in optic neuropathy subjects than control subjects for both dim and bright stimuli ( = .002, <0.0005). There was no overlap between groups for C and C for either stimulus.: A portable pupillometer was implemented on a commercial portable electroretinography platform and applied in a pilot manner to subjects with and without unilateral optic neuropathies. Optic neuropathy eyes were distinguished from non-optic neuropathy eyes both within and between subjects.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339172 | PMC |
http://dx.doi.org/10.1080/02713683.2021.1878542 | DOI Listing |
Front Immunol
January 2025
Department of Geriatric Medicine, Affiliated Hospital of Qingdao University, Qingdao, China.
Objective: This study aims to delineate the clinical features underlying the concurrent disease of neuromyelitis optica spectrum disorder (NMOSD) and myasthenia gravis (MG), and to identify efficacious therapeutic strategies.
Background: NMOSD and MG are uncommon autoimmune diseases that infrequently co-exist. Despite previous reports, a consensus on treating NMOSD concurrent with MG is lacking.
J Cell Biol
April 2025
Department of Genetics and Cell Biology, College of Life Sciences, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China.
TBC1D20 deficiency causes Warburg Micro Syndrome in humans, characterized by multiple eye abnormalities, severe intellectual disability, and abnormal sexual development, but the molecular mechanisms remain unknown. Here, we identify TBC1D20 as a novel Rab11 GTPase-activating protein that coordinates vesicle transport and actin remodeling to regulate ciliogenesis. Depletion of TBC1D20 promotes Rab11 vesicle accumulation and actin deconstruction around the centrosome, facilitating the initiation of ciliogenesis even in cycling cells.
View Article and Find Full Text PDFNeuro Oncol
January 2025
Department of Neurology, Division of Infectious Diseases, Washington University School of Medicine, St. Louis MO 63110 USA.
Background: The intestinal microbiota regulates normal brain physiology and the pathogenesis of several neurological disorders. While prior studies suggested that this regulation operates through immune cells, the underlying mechanisms remain unclear. Leveraging two well characterized murine models of low-grade glioma (LGG) occurring in the setting of the neurofibromatosis type 1 (NF1) cancer predisposition syndrome, we sought to determine the impact of the gut microbiome on optic glioma progression.
View Article and Find Full Text PDFFront Immunol
January 2025
Genentech, Inc., South San Francisco, CA, United States.
Objectives: This case series describes adults with aquaporin 4 immunoglobulin G-seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD) who switched treatment from eculizumab to satralizumab.
Methods: Case information for patients with AQP4-IgG+ NMOSD who received satralizumab for ≥6 months was obtained from US healthcare providers from April 2022 to January 2024. Patient characteristics, examination findings, diagnostic test results, treatment response, and adverse events were recorded.
Cureus
December 2024
Cornea and Refractive Surgery, Al-Shifa Trust Eye Hospital, Rawalpindi, PAK.
Background: Glaucoma, particularly open-angle glaucoma (OAG), is a leading cause of irreversible blindness, associated with optic nerve damage, retinal ganglion cell death, and visual field defects. Corneal biomechanical properties and cellular components, such as corneal nerve and keratocyte densities assessed by in vivo confocal microscopy (IVCM), may serve as biomarkers for glaucoma progression. This study aimed to explore the relationship between corneal nerve parameters, keratocyte density, and optical coherence tomography (OCT)-derived retinal nerve fiber layer (RNFL) thickness in primary open-angle glaucoma (POAG) patients and controls.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!